Thumbnail

Brazil Diabetes Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Looking to buy the report?

The market growth of diabetic devices is directly proportional to the increasing diabetic population in the country. Brazil is among the 10 countries with the highest prevalence of diabetes in the world (about 7.6%). Diabetes is the fifth underlying cause of death in Brazil, affecting 2.5% of the population. There are almost 19.5 million people living with diabetes in the country, and close to 1.5 million are undiagnosed diabetic population. Type 2 diabetes accounts for close to 90% of the diabetic population in the country.  The increasing number of type 2 diabetic population has a direct correlation to the growing obesity among the population. According to a study conducted by the ministry of health in 2011, close to 42% of the population in the country is either obese or overweight. The Type 1 diabetic population is expected to see an average increase of 3.1% per year, from 2012-2023. The increasing diabetic population acts as a prominent driver for the diabetic devices market in Brazil.

The Brazilian diabetes devices market is broadly segmented based on type, into glucose monitoring devices market and management devices market. The glucose monitoring devices market is further segmented into blood glucose meter, blood glucose testing strip, lancet, and continuous glucose monitoring device (CGM). Based on insulin delivery devices, the management devices market is further segmented into syringes, pens, pumps, and injectors.

In the insulin delivery devices market in Brazil, the insulin cartridge market and the insulin pens market account for the highest market shares.  The growing demand for insulin has led to tremendous R&D in manufacturing different painless types of insulin deliverable devices, such as CGMs. Initially, syringes were the only form of insulin delivery systems, but they are considered to be painful and not user-friendly. Thus, companies like Novo Nordisk and Sanofi, among others, have produced their own insulin pens. They have a specific set dosage and are not only less painful to use, but also reduces the wastage of insulin. The high cost of insulin pens is the only prominent restraining factor for the growth of the insulin pens market.

Brazil has a high number of diabetic patients, which accelerates the growth of the devices market. The insulin delivery devices market accounts for 54% of the total Brazilian devices market.  The Brazilian insulin delivery devices market was valued at USD 423 million in 2017, and it is expected to witness a CAGR of 3.86 % during the forecast period (2018-2023). The revenue share of insulin pens and cartridges market accounted for 32% of the devices market.

Source: Mordor Intelligence Analysis

Key Players:  

Dexcom, Abbott, Johnson and Johnson, Ok biotech, Medtronic, Novo Nordisk, Insujet, Sanofi, and Eli Lilly, among others

Key Developments:

Feb 2018: Dexcom acquired TypeZero Technologies, paving the way for automated insulin delivery. The acquisition has set Dexcom ahead on its way in the race to create an artificial pancreas system, rather than simply offering a continuous glucose monitoring device.

Report Scope:

Attribute

Details

The base year for estimation

2017

Review Period

2012-2017

Forecast Period

2018 – 2023

Market Representation

Revenue in USD billion and CAGR from 2018 – 2023

Regions covered

Brazil

Report coverage

Revenue forecast and market dynamics

Reasons to Purchase this Report:

  • The current and future market outlook in the Brazilian diabetes devices market
  • Various perspectives of the market with the help of Porter’s five forces analysis
  • Detailed analysis of the segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • The latest developments and strategies employed by the major market players
  • 3-month analyst support, along with the Market Estimate sheet in Excel

Report Customization and Benefits:

This report can be customized to meet the desired requirements. Please connect with our analyst, who will ensure that you will get a report that suits your needs.

1. Introduction

                1.1 Scope of Study

                1.2 Market Definition

                1.3 Executive Summary

2. Research Methodology

                2.1 Study Deliverables

                2.2 Study Assumptions

                2.3 Research Phases

3. Market Insights

                3.1 Technology Trends

                3.2 Industry Attractiveness - Porter's Five Forces Analysis

                                3.2.1 Bargaining Power of the Suppliers

                                3.2.2 Bargaining Power of the Consumers

                                3.2.3 Threat of New Entrants

                                3.2.4 Threat of Substitute Products and Services

                                3.2.5 Competitive Rivalry within the Industry

4.  Market Dynamics

                4.1 Drivers

                4.2 Restraints

                4.3 Opportunities

5. Market Indicators

                5.1 Total Diabetes Population

                5.2 Type 1 Diabetes Population

                5.3 Type 2 Diabetes Population

6. Market Segmentation and Analysis

                6.1 Monitoring Device

                                6.1.1 Self Blood Glucose Monitoring

                                                6.1.1.1 Glucometer Device

                                                                6.1.1.1.1 Blood Glucose Meters

                                                                                6.1.1.1.1.1 Blood Glucose Meters, Revenue (2012-2023)

                                                                                6.1.1.1.1.2 Blood Glucose Meters, Volume (2012-2023)

                                                6.1.1.2 Glucometer consumables

                                                                6.1.1.2.1 Blood Glucose Test strips

                                                                                6.1.1.2.1.1 Blood Glucose Test strips, Revenue (2012-2023)

                                                                                6.1.1.2.1.2 Blood Glucose Test strips, Volume (2012-2023)

                                                                6.1.1.2.2 Lancets

                                                                                6.1.1.2.2.1 Lancets, Revenue (2012-2023)

                                                                                6.1.1.2.2.2 Lancets, Volume (2012-2023)

                                6.1.2 Continuous Blood Glucose Monitoring

                                                6.1.2.1 Durables

                                                                6.1.2.1.1 Durables, Revenue (2012-2023)

                                                                6.1.2.1.2 Durables, Volume (2012-2023)

                                                6.1.2.2 Sensors

                                                                6.1.2.2.1 Sensors, Revenue (2012-2023)

                                                                6.1.2.2.2 Sensors, Volume (2012-2023)

                6.2 Management Device

                                6.2.1 Insulin Pump

                                                6.2.1.1 Insulin Pump Device

                                                                6.2.1.1.1 Insulin Pump Devices, Revenue (2012-2023)

                                                                6.2.1.1.2 Insulin Pump Devices, Volume (2012-2023)

                                                6.2.1.2 Insulin Pump Reservoir

                                                                6.2.1.2.1 Insulin Pump Reservoirs, Revenue (2012-2023)

                                                                6.2.1.2.2 Insulin Pump Reservoirs, Volume (2012-2023)

                                                6.2.1.3 Infusion Set

                                                                6.2.1.3.1 Infusion Sets, Revenue (2012-2023)

                                                                6.2.1.3.2 Infusion Sets, Volume (2012-2023)

                                6.2.2 Syringes

                                                6.2.2.1 Syringes, Revenue (2012-2023)

                                                6.2.2.2 Syringes, Volume (2012-2023)

                                6.2.3 Cartridges

                                                6.2.3.1 Cartridges, Revenue (2012-2023)

                                                6.2.3.2 Cartridges, Volume (2012-2023)

                                6.2.4 Disposable Pens

                                                6.2.4.1 Disposable Pens, Revenue (2012-2023)

                                                6.2.4.2 Disposable Pens, Volume (2012-2023)

                                6.2.5 Jet Injectors

                                                6.2.5.1 Jet Injectors, Revenue (2012-2023)

                                                6.2.5.2 Jet Injectors, Volume (2012-2023)

7. Key Player Profiles

                7.1 Abbott Diabetes Care

                7.2 Roche

                7.3 Johnson & Johnson

                7.4 Arkray

                7.5 Ascensia Diabetes Care

                7.6 AgaMatrix, Inc.

                7.7 LifeScan

                7.8 Sanofi

                7.9 Dexcom

                7.10 Medtronic

                7.11 Novo Nordisk

                7.12 Becton Dickinson

                7.13 Eli Lilly

                7.14 Novonordisk

                7.15 Ypsomed Holding AG

* Each Company Profile include overview, Revenue, Product and services, Swot, Recent Activities and strategic Analysis.

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy